Naltrexone can dampen the reward you get from eating highly palatable foods, and when combined with bupropion it shows measurable effects on specific types of cravings, particularly for fatty and savory items. But the relationship between naltrexone and food cravings is not as straightforward as “take a pill, stop craving cookies.” Whether and how much it helps depends on what is driving your cravings, whether you take naltrexone alone or as part of a combination, and what other support you have in place. The evidence is a patchwork of strong signals and surprising gaps.
How Naltrexone Changes the Way Food Feels
Naltrexone is an opioid receptor blocker. Most people associate it with alcohol or opioid addiction treatment, but the same brain circuitry it targets is deeply involved in the pleasure side of eating. Your brain’s opioid system doesn’t just handle pain relief; it also processes how rewarding food tastes. Animal research has shown that opioid signaling in reward-related brain regions selectively boosts consumption of preferred flavors, and that blocking those receptors with naltrexone selectively decreases intake of the more-preferred option.
In human studies, naltrexone has been shown to reduce how pleasant food tastes, not uniformly across all foods, but with the strongest effects on sweet, fatty, and high-protein items. A study measuring pleasantness ratings found that naltrexone significantly lowered how enjoyable these types of foods were rated compared to placebo.
Here is where it gets interesting, though: even when naltrexone reduced how good sweet foods tasted, it didn’t always reduce how much of them people ate. Intake of sweet foods was relatively spared compared to other categories.
Why Pleasantness and Cravings Are Not the Same Thing
This distinction between liking and wanting matters. Naltrexone consistently makes food taste less rewarding, but a craving is a more complex experience than just finding something delicious. Cravings involve anticipation, emotional triggers, habit loops, and sometimes genuine hunger signals. Naltrexone’s main lever is the hedonic reward piece, the “this tastes amazing” part. If your craving is driven primarily by the pleasure you expect from eating something, naltrexone has a clear pathway to help. If your craving is driven by stress, boredom, or a conditioned habit, the drug is targeting only one component of a multi-part problem.
A small pilot study in women with obesity explored this directly. When the researchers looked at overall craving intensity, neither 25 mg nor 50 mg naltrexone doses significantly reduced cravings compared to placebo across all participants. But when they accounted for each person’s level of reward-based eating drive, a telling pattern emerged: among people who scored high on reward-driven eating, the 50 mg dose disrupted the link between that drive and craving intensity. On placebo days, high reward-drive participants had strong cravings. On naltrexone days, that connection faded to statistical insignificance.
The takeaway is that naltrexone’s craving effects are not one-size-fits-all. They appear most meaningful in people whose eating is heavily reward-driven rather than stress-driven or habitual.
The Bupropion Combination and Why It Exists
Naltrexone is rarely prescribed alone for food cravings or weight management. The approved weight-loss medication pairs it with bupropion (an antidepressant that also affects dopamine and norepinephrine). The two drugs work on different parts of the same appetite-regulation pathway. Bupropion stimulates a group of brain cells called POMC neurons in the hypothalamus, which help suppress appetite. But these neurons have a built-in brake: they release their own opioid signals that loop back and dampen their own activity. Naltrexone blocks that self-inhibition, allowing bupropion’s appetite-suppressing effect to persist longer and more strongly.
Research into the brain-level effects of this combination suggests it alters how the brain reacts to food cues, though the full neurobiological picture is still not completely mapped out.
In terms of craving-specific outcomes, a pooled analysis of clinical trial data found that the naltrexone/bupropion combination outperformed placebo on several craving measures. Patients on the combination reported better craving control, improved positive mood around eating, and reduced cravings specifically for savory foods, high-fat foods, and fast-food fats.
What Kinds of Cravings Respond Best
The craving reductions seen with naltrexone, both alone and combined with bupropion, are not evenly distributed across food types. This is consistent with the underlying pharmacology: opioid receptors are more involved in the reward value of some flavors and textures than others.
When naltrexone was given alone, it reduced the pleasantness of sweet, fatty, and high-protein foods more than other categories.
The combination with bupropion showed its strongest craving reductions for savory, high-fat, and fast-food items specifically.
In people with binge-eating disorder, one laboratory study found that naltrexone/bupropion reduced craving for preferred high-caloric sweet snacks and lowered total calorie consumption, though it did not change the decision to start eating.
If your cravings center on rich, fatty, or savory comfort foods, the existing evidence aligns better with a potential benefit than if your cravings are mostly for, say, fruit or bread. That said, the research on food-type-specific craving reduction is still relatively thin, and individual responses will vary.
Binge-Eating Disorder and Mixed Results
Binge-eating disorder (BED) involves recurrent episodes of eating large amounts of food with a feeling of loss of control, and food cravings are a central feature. You might expect naltrexone-based treatments to be a natural fit, but the evidence is genuinely mixed.
A randomized controlled pilot study gave naltrexone/bupropion or placebo to people with BED and obesity for 12 weeks. Both groups improved substantially: binge-eating frequency dropped, eating-disorder symptoms eased, depression scores fell, and weight decreased. But the improvements with the drug did not significantly differ from placebo. At six-month follow-up, outcomes remained improved in both groups with no significant separation.
A larger trial took a different approach, testing naltrexone/bupropion as a maintenance treatment in people who had already responded to it during an acute phase. Here the results were more encouraging. Among those who responded initially and then continued on the active drug, about 69% maintained binge-eating remission, compared to 50% who were switched to placebo. The placebo group also experienced more return of binge-eating and did not lose additional weight.
A separate trial that combined naltrexone/bupropion with behavioral weight loss therapy found binge-eating remission rates of about 57% in the combined group, compared with roughly 37% for behavioral therapy alone, 31% for medication alone, and 18% for placebo.
The picture that emerges for BED is that naltrexone/bupropion can contribute meaningfully, but it works best as part of a broader treatment approach and may be more valuable for maintaining gains than for producing them in the first place.
The Behavioral Therapy Question
One of the most important findings in this area is easy to miss. In the COR-BMOD trial, which tested naltrexone/bupropion alongside an intensive behavioral modification program involving a reduced-calorie diet plan, increased physical activity, and structured behavioral coaching, both the drug group and the placebo group saw similar reductions on the Food Craving Inventory at all assessment points through 56 weeks. There were no significant differences between groups on craving scores at any time.
The drug group still lost significantly more weight (about 9.3% versus 5.1% in the intention-to-treat analysis), so the combination was clearly doing something beyond what behavioral modification alone achieved.
What this suggests is that when people are already receiving strong behavioral support, the additional craving reduction from the medication may be small or undetectable by self-report measures, even though the metabolic and appetite effects still produce greater weight loss. It is possible the drug works partly through mechanisms beyond subjective craving, like reducing caloric intake at meals or shifting food preferences in ways people don’t consciously register as “less craving.”
For people without access to intensive behavioral support, the craving effects of the medication might be more noticeable and more practically important. The pooled analysis showing craving improvements with naltrexone/bupropion over placebo was based on broader clinical trial populations, not specifically the intensive-behavioral-support group.
Side Effects and Why So Many People Stop
Any discussion of whether naltrexone helps with cravings has to reckon with the fact that a lot of people stop taking it. In real-world data from a European clinical setting, more than half of patients discontinued naltrexone/bupropion within 12 months. During the dose buildup phase, about 24% experienced nausea or vomiting, roughly 19% had headaches, and about 29% reported constipation. Once patients reached the full dose, nearly 40% experienced side effects, with a third reporting multiple symptoms.
Nausea is the most talked-about side effect and the one most likely to drive early discontinuation. In clinical trial data, about 6% of patients on the combination quit specifically because of nausea, compared to essentially zero in the placebo group. An additional 18% discontinued due to other adverse events, versus about 12% on placebo.
The weight loss produced by the combination appears to be independent of nausea, meaning the drug is not just making people lose weight because they feel too sick to eat.
For people interested in naltrexone specifically for craving control, the practical question is whether the craving benefits hold up if you can tolerate the side effects long enough. The dose-escalation schedule used with the combination (starting low and building up over several weeks) exists partly to improve tolerability, but even with gradual increases, dropout remains high.
How Much Weight Does It Actually Produce
If you are considering naltrexone or naltrexone/bupropion specifically for cravings, you probably also want to know how the weight-loss numbers stack up. Across clinical trials, the naltrexone/bupropion combination reduced body weight by roughly 3% more than placebo over 56 weeks.
That is a real but modest effect compared to newer GLP-1 receptor agonist medications. When paired with intensive behavioral modification, the absolute numbers look better: about 9.3% weight loss versus 5.1% for placebo with the same behavioral program.
The craving angle matters here because the drug’s appeal is not raw weight-loss power but the specific help it offers with the reward and craving aspects of eating that many people find hardest to manage on their own.
After Bariatric Surgery
An emerging area of use is prescribing naltrexone/bupropion to people who have had bariatric surgery and are experiencing weight regain. Weight regain after surgery is common and frequently accompanied by the return of food cravings and emotional eating patterns.
Real-world data suggest that naltrexone/bupropion is equally effective in people who have never had surgery and in those experiencing post-surgical weight regain, regardless of the dose reached.
In clinical practice, prescribers have observed a natural selection pattern: patients whose post-surgical struggles center on emotional hunger and food cravings tend to gravitate toward naltrexone/bupropion, while those whose main issue is poor satiety (not feeling full) tend to be directed toward GLP-1 receptor agonist medications instead. This makes intuitive sense given the different mechanisms involved: naltrexone/bupropion targets reward circuitry, while GLP-1 drugs primarily slow gastric emptying and signal fullness.
Genetics and Whether It Will Work for You
There has been interest in whether a common genetic variant in the mu-opioid receptor gene (known as A118G) might predict who responds to naltrexone. The logic is appealing: if naltrexone blocks opioid receptors, and some people have a slightly different version of those receptors, maybe genetics could tell us in advance who will benefit most.
So far, the evidence is not encouraging for this idea. A study that tested opioid antagonists in healthy volunteers, looking at both alcohol-related and food-related behaviors and stratifying participants by their opioid receptor genotype, found no strong evidence that the genetic variant changed how well the drugs worked. The researchers concluded that their results did not support strong modulatory effects of this particular genetic variation on opioid receptor antagonist effects related to food.
This does not mean genetics are irrelevant to naltrexone response. It means the most-studied candidate gene has not panned out as a useful predictor. Personalized medicine for food-craving treatment is not yet a reality, and prescribing decisions are still based on clinical characteristics, not genetic testing. The reward-based eating profile described in the pilot study, where people with higher reward-driven eating tendencies showed more craving benefit from naltrexone, may end up being a more practical way to identify good candidates than genotyping.